# PT-141 reported effects, tolerability, and safety — bremelanotide > PT-141 (bremelanotide) effects and safety: what trials measured, what people in research-use communities report (labeled anecdotal), and the cited cautions — presented as an editorial dossier, not medical advice. The measured clinical effects, the honest tolerability cost, what people in research-use communities report, and the cited cautions — each layer kept clearly separate so nothing anecdotal is mistaken for a trial result. ## The short version In plain words: in the one group PT-141 is approved for — premenopausal women with distressing low desire — the RECONNECT Phase 3 trials showed a real but modest gain in sexual desire and a small drop in the distress that came with it [4]. The effect is central rather than vascular: the drug acts on melanocortin receptors in the brain, and a 2022 brain-imaging study confirmed the mechanism raises desire for up to 24 hours [23]. The tolerability cost is significant. Nausea is common — roughly four in ten over long-term use — and is the principal reason people stop [5]. A transient blood-pressure rise after each dose means the label contraindicates use in uncontrolled hypertension or known cardiovascular disease [24]. With frequent repeated dosing, skin, gum, and breast darkening can occur through activation of pigment-making receptors [24]. None of what follows is medical advice. The measured clinical effects come first; what people in research-use communities describe is in its own clearly marked section so anecdotal accounts are never confused with trial results. ## What the trials measured The pivotal evidence sits in RECONNECT, two matched Phase 3 randomized, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with acquired, generalized HSDD. Subcutaneous bremelanotide 1.75 mg on demand produced statistically significant improvements on both co-primary endpoints versus placebo over 24 weeks: FSFI Desire domain change of +0.35 versus +0.21 (p<0.001) and FSDS-DAO-13 distress item change of −0.74 versus −0.42 (p<0.001) [4]. A 52-week open-label extension in 684 women found desire improvements held without new safety signals; the most common drug-related events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [5]. A mechanistic fMRI study in 31 premenopausal women with HSDD showed that MC4R agonism increased sexual desire for up to 24 hours and enhanced amygdala-insula functional connectivity in response to erotic stimuli — direct imaging evidence of a central brain effect on desire [23]. In men, earlier phase work found rapid dose-dependent erectile activity, but that use was never approved and remains investigational [25]. The benefit is real but modestly sized and debated in the literature. Reviewers note the trial populations were specifically premenopausal women with acquired, generalized HSDD, and caution against generalizing to other groups [13]. ## What people report **These are accounts from research-use and community discussion — anecdotal, not clinical evidence — and are kept separate from the cited trial findings above on purpose. No doses are attached to any of them.** The most commonly reported benefit is a stronger sense of sexual desire and 'wanting' — people describe the drive as coming from the brain rather than the body, different from what blood-flow drugs produce. Frequently reported alongside that are greater physical arousal and sensitivity, and easier or more intense orgasm, though experiences vary widely. People who use it off-label for men describe spontaneous erections and desire-first rather than erection-first sexual interest; this is off-label use outside the approved indication. A frequently noted pattern is delayed onset of one to several hours with a long window of effect that can persist into the following day. On the adverse side: nausea is by far the most commonly described complaint and the one most likely to make people stop — consistent with the trial record. Flushing and reddening of the face and neck are frequently reported, headache is common and generally mild, and injection-site soreness is often mentioned. Occasionally: tingling, brief anxiety, fatigue for several hours, and with frequent dosing, darkening of skin, gums, or moles that was not always reversible after stopping. A real recurring report is no effect at all while still experiencing side effects — responses are highly individual. ## Safety and cautions The cautions below come from the trial record and the label; theoretical or mechanistic ones are marked as such. **Approved only for one group.** Bremelanotide is approved only for acquired, generalized HSDD in premenopausal women. Use in men, in postmenopausal women, or for performance is off-label or investigational [24][26][4]. **Blood pressure and cardiovascular.** A transient blood-pressure rise occurs after each dose — averaging roughly +6/+3 mmHg systolic/diastolic, peaking at two to four hours, returning to baseline within 12 hours. The label contraindicates use in uncontrolled hypertension or known cardiovascular disease [24][27]. **Nausea.** Affects approximately 40% of users over long-term use; the leading reason for discontinuation. Worst with the first dose and tends to ease with repeated use [5][13]. **Pigmentation with frequent dosing.** Repeated frequent dosing has produced darkening of the face, gums, and breasts through MC1R activation in skin. Darkening may not fully reverse after stopping. The dosing-frequency limits exist partly to manage this [24]. **Liver signal.** The NIH LiverTox record notes mild aminotransferase elevations and, rarely, clinically apparent liver injury — uncommon but documented [21]. **Research-chemical supply.** Material sold as a research chemical has no pharmaceutical oversight of identity, purity, or concentration. Forensic analysis confirms unregulated melanocortin peptides circulate, and case reports of self-injected related peptides document serious harms including rhabdomyolysis [28][29]. **Appetite effects (theoretical/off-target).** MC4R sits in appetite-regulating circuits; high-frequency research-protocol dosing reduced food intake and body weight in phase 1 work [30]. A pharmacological consideration, not an approved or recommended use. **Pregnancy and breastfeeding.** No controlled human data establish safety for a developing fetus or nursing infant. Treat as unsupported. (Theoretical — no study establishes harm or safety in these groups.) This dossier recommends no dose and gives no treatment instruction. ## Then and now PT-141 grew out of melanotan II, an earlier synthetic melanocortin peptide explored first for skin tanning in the 1990s. Researchers noticed that melanotan II also produced sexual effects, and the compound was re-engineered — cyclized and modified — to target sexual function rather than pigmentation. The resulting molecule, bremelanotide, was first studied as a nasal spray and then by injection across early and mid-phase trials for erectile dysfunction and female sexual problems through the 2000s. Development later concentrated on women with low sexual desire, advancing through the RECONNECT Phase 3 program. In June 2019 the FDA approved bremelanotide injection (NDA 210557) for acquired, generalized HSDD in premenopausal women, placing it among the notable peptide drug approvals of that year [26][31][25][4][24]. --- An indexed dossier of peer-reviewed bremelanotide research — not a clinic, not a vendor, nothing prescribed or dispensed here.